<DOC>
	<DOCNO>NCT01661257</DOCNO>
	<brief_summary>This study investigate expression T-cell immunoglobulin- mucin-domain-containing molecule 3 ( TIM-3 ) colonic mucosa and/or peripheral blood child Crohn 's disease anti TNF-α ( infliximab ) therapy .</brief_summary>
	<brief_title>Expression TIM-3 Correlation With Disease Activity Pediatric Crohn 's Disease With Anti TNF-α Therapy</brief_title>
	<detailed_description>The immunoregulatory effect TIM-3 patient Crohn 's disease accord treatment yet investigate .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>•Pediatric patient diagnose severe Crohn 's disease require infliximab treatment confirm diagnostic Crohn 's disease clinical , endoscopic histological finding •patients proven infliximab antibody</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Crohn 's disease</keyword>
	<keyword>Infliximab</keyword>
	<keyword>T-cell immunoglobulin- mucin-domain-containing molecule 3 ( TIM-3 )</keyword>
</DOC>